varied outcomes in patients with aml harboring poor-risk cytogenetics with or without tp53 mutation
Published 10 months ago • 48 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
1:14
predicting patient response to btk inhibitors using novel approaches
-
0:59
mitigating cardiological toxicities associated with btki in b-cell malignancies
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
7:05
hematology oncology rotation | day in the life of a doctor | vlog | bookworm_md
-
8:32
chronic lymphocytic leukemia (cll) - etiology, risk factors, symptoms, signs, diagnosis, treatment
-
3:30
gene therapy basics
-
1:28
risk factors associated with ta-tma in patients with gvhd
-
2:57
novel targeted therapies for the treatment of bpdcn
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
2:33
btki resistance and it's management
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
2:41
an overview of the latest advances in hematology
-
2:02
key questions about the future of cll
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo